IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 520
- Registration Number
- NCT02450526
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke
- Conditions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT02444494
- Locations
- 🇵🇱
Indywidualna Praktyka lekarska, Ciecierzyn, Poland
🇵🇱Samodzielny Publiczny Centralny Szpital Kliniczny im, Śląskiego Uniwersytetu Medycznego w Katowicach Oddział Neurologii Wieku Podeszłego, Katowice, Poland
🇵🇱Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Sandomierzu - Szpital - Oddział Neurologii z Pododdziałem Udarowym, Sandomierz, Poland
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 28
- Registration Number
- NCT02396953
- Locations
- 🇷🇺
Kazan state Medical Academy, Kazan, Russian Federation
🇷🇺North-Western State Medical University, Saint-Petersburg, Russian Federation
🇫🇷CHU le BOCAGE, Dijon, France
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
- Conditions
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 152
- Registration Number
- NCT02396966
Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients
- Conditions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 239
- Registration Number
- NCT02390206
- Locations
- 🇧🇷
Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
🇧🇷Centro Catarinense de Reabilitação, Florianópolis, Brazil
🇧🇷Hospital Bettina Ferro de Souza Campus IV da Universidade Federal do Pará, Belém, Brazil
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke
- Conditions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 57
- Registration Number
- NCT02384330
- Locations
- 🇵🇹
Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal
🇵🇹C. H. T. M. A. D. - Unidade Hospitalar de Vila Real, Vila Real, Portugal
🇵🇹C. H. A. - Hospital de Faro, Faro, Portugal
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 43
- Registration Number
- NCT02365584
- Locations
- 🇮🇹
Ospedale Sacro Cuore di Gesù - Fatebenefratelli, Benevento, Italy
🇮🇹Ospedale San Raffaele IRCCS, Ginecologia oncologica, Milano, Italy
🇮🇹Ospedali riuniti Ancona- Dipartimento Medicina Interna - Clinica Oncologica, Ancona, Italy
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 185
- Registration Number
- NCT02353871
- Locations
- 🇫🇷
Mediti, Juan les Pins, France
🇫🇷Nouvelle Clinique Bel Air, Bordeaux, France
🇩🇪Hautzentrum am Starnberger See, Starnberg, Germany
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
- Conditions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT02353897
- Locations
- 🇦🇺
ERASE, Malvern, Australia
🇰🇿Laser Center DARUS, Almaty, Kazakhstan
🇨🇿BcD Clinic s.r.o., Praha, Czechia
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 54
- Registration Number
- NCT02321475
- Locations
- 🇷🇺
Russian National Research Medical University, Moscow, Russian Federation
🇷🇺First Moscow State Medical University, Moscow, Russian Federation